<?xml version="1.0" encoding="UTF-8"?>
<p>Vaccinating infants with an improved TB vaccine would represent an important public health benefit over the long term but would not have as great an impact before 2050 as would an adolescent/adult vaccine, mainly because infants and young children are not an important source of 
 <italic>Mtb</italic> spread. Accordingly, the public health impact of an infant vaccine would be delayed until adolescence, when the burden of 
 <italic>Mtb</italic> infection, and the possibility of spreading 
 <italic>Mtb</italic> to others, increases. Moreover, an infant vaccine would need to demonstrate higher efficacy and/or longer durations or protection than a vaccine administered to adolescents and adults to have an important, and cost effective, effect on public health 
 <sup>
  <xref rid="ref-7" ref-type="bibr">7</xref>
 </sup>. Mathematical modeling of the impact of vaccinating infants extends to the year 2050. Beyond that, there is too much uncertainty to draw conclusions with confidence.
</p>
